Article
Neoadjuvant pembrolizumab, dabrafenib and trametinib in BRAFV600-mutant resectable melanoma: the randomized phase 2 NeoTrio trial.
Nature medicine - 1 Sept 2024
Long Georgina V, Carlino Matteo S, Au-Yeung George, Spillane Andrew J, Shannon Kerwin F, Gyorki David E, Hsiao Edward, Kapoor Rony, Thompson Jake R, Batula Iris, Howle Julie, Ch'ng Sydney, Gonzalez Maria, Saw Robyn P M, Pennington Thomas E, Lo Serigne N, Scolyer Richard A, Menzies Alexander M
Abstract excerpt
Immune checkpoint inhibitors and BRAF-targeted therapy each improve survival in melanoma. Immune changes early during targeted therapy suggest the mechanisms of each drug class could work synergistically. In the non-comparative, randomized, phase 2 NeoTrio trial, we investigated whether targeted therapy could boost the proportion of patients achieving long-term recurrence-free survival with neoadjuvant...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.